143 related articles for article (PubMed ID: 21892801)
1. [Promising approaches of translational research in head and neck cancer].
Dietz A
HNO; 2011 Sep; 59(9):857-8. PubMed ID: 21892801
[No Abstract] [Full Text] [Related]
2. [Best supportive care in head and neck cancer].
Salzwimmer M
Wien Med Wochenschr; 2008; 158(9-10):278-82. PubMed ID: 18560955
[TBL] [Abstract][Full Text] [Related]
3. [Translational research in head and neck cancer. Biological characteristics and general aspects].
Dietz A; Wichmann G
HNO; 2011 Sep; 59(9):874-84. PubMed ID: 21861150
[TBL] [Abstract][Full Text] [Related]
4. [Current therapy options in recurrent head and neck cancer].
Boehm A; Wichmann G; Mozet C; Dietz A
HNO; 2010 Aug; 58(8):762-9. PubMed ID: 20628714
[TBL] [Abstract][Full Text] [Related]
5. [Development, current status and perspectives of tumor therapy in oromandibulofacial surgery--a determination of the current status].
Hausamen JE; Eckardt A; Schmelzeisen R
Fortschr Kiefer Gesichtschir; 1994; 39():5-12. PubMed ID: 8088670
[No Abstract] [Full Text] [Related]
6. [Current status of head and neck cancer therapy in the elderly].
Sesterhenn AM
Laryngorhinootologie; 2007 Feb; 86(2):95-100. PubMed ID: 17219330
[TBL] [Abstract][Full Text] [Related]
7. New developments for optimal management of head and neck cancer.
de Bree R; Leemans CR
Onkologie; 2004 Aug; 27(4):339-42. PubMed ID: 15376363
[No Abstract] [Full Text] [Related]
8. Aggressive concurrent chemoradiotherapy for squamous cell head and neck cancer: an 8-year single-institution experience.
Lavertu P; Adelstein DJ; Saxton JP; Secic M; Eliachar I; Strome M; Larto MA; Wood BG
Arch Otolaryngol Head Neck Surg; 1999 Feb; 125(2):142-8. PubMed ID: 10037279
[TBL] [Abstract][Full Text] [Related]
9. Which is the single most important factor in deciding the management and determining the prognosis of head and neck cancer?
Ferlito A; Takes RP; Rinaldo A; Devaney KO
Eur Arch Otorhinolaryngol; 2010 Mar; 267(3):325-6. PubMed ID: 19823861
[No Abstract] [Full Text] [Related]
10. [Relevance of colour-duplex echography for detection and therapy of recurrences in the follow-up of head and neck cancer].
Di Martino E; Hausmann R; Krombach GA; Nowak B; Tietze L; Gagel B; Zimny M; Westhofen M
Laryngorhinootologie; 2002 Dec; 81(12):866-74. PubMed ID: 12486624
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by chemoradiotherapy or chemoradiotherapy alone in stage III-IV unresectable head and neck cancer: Results of a randomized phase II study.
Takácsi-Nagy Z; Hitre E; Remenár É; Oberna F; Polgár C; Major T; Gödény M; Fodor J; Kásler M
Strahlenther Onkol; 2015 Aug; 191(8):635-41. PubMed ID: 25782685
[TBL] [Abstract][Full Text] [Related]
12. Circulating and disseminated tumour cells in head and neck cancer.
Harris AT; Derbyshire S; Wilson J; Loh C; Kinshuck AJ; Attlmayr B; Jones TM
J Laryngol Otol; 2015 Sep; 129(9):826-30. PubMed ID: 26174011
[TBL] [Abstract][Full Text] [Related]
13. Unresectable primary and recurrent head and neck tumors: effect of hyperthermia and carboplatin--preliminary experience.
Chang P; Sapozink MD; Grunberg SM; Jozsef G; Rice DM; Formenti SC; Streeter OE
Radiology; 2000 Mar; 214(3):688-92. PubMed ID: 10715031
[TBL] [Abstract][Full Text] [Related]
14. The dilemma of follow-up in head and neck cancer patients.
Haas I; Hauser U; Ganzer U
Eur Arch Otorhinolaryngol; 2001 May; 258(4):177-83. PubMed ID: 11407449
[TBL] [Abstract][Full Text] [Related]
15. Impact of intensity-modulated and image-guided radiotherapy on elderly patients undergoing chemoradiation for locally advanced head and neck cancer.
Nguyen NP; Vock J; Chi A; Vinh-Hung V; Dutta S; Ewell L; Jang S; Betz M; Almeida F; Miller M; Davis R; Sroka T; Vo RP; Karlsson U; Vos P
Strahlenther Onkol; 2012 Aug; 188(8):677-83. PubMed ID: 22659942
[TBL] [Abstract][Full Text] [Related]
16. [p53 mutations/p53 protein overexpression. Differential significance for the progression of head-neck carcinomas].
Bosch FX; Homann N; Conradt C; Dietz A; Erber R
HNO; 1999 Sep; 47(9):833-48. PubMed ID: 10525616
[No Abstract] [Full Text] [Related]
17. Hyperfractionated accelerated radiation therapy plus cetuximab plus cisplatin chemotherapy in locally advanced inoperable squamous cell carcinoma of the head and neck : Final 5‑year results of a phase II study.
Kuhnt T; Schreiber A; Pirnasch A; Hautmann MG; Hass P; Sieker FP; Engenhart-Cabillic R; Richter M; Dellas K; Dunst J
Strahlenther Onkol; 2017 Sep; 193(9):733-741. PubMed ID: 28500491
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of CXCL12 and CXCR4 in inoperable head and neck squamous cell carcinoma.
Rave-Fränk M; Tehrany N; Kitz J; Leu M; Weber HE; Burfeind P; Schliephake H; Canis M; Beissbarth T; Reichardt HM; Wolff HA
Strahlenther Onkol; 2016 Jan; 192(1):47-54. PubMed ID: 26374452
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors in squamous cell carcinoma of the head and neck.
Wendt TG; Bank P
Onkologie; 2002 Jun; 25(3):208-12. PubMed ID: 12119454
[TBL] [Abstract][Full Text] [Related]
20. Gene therapy for head and neck cancer.
Gleich LL
Laryngoscope; 2000 May; 110(5 Pt 1):708-26. PubMed ID: 10807351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
